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Abstract: Cancers express tryptophan catabolising enzymes indoleamine 2,3-dioxygenase 1 (IDO1)
and tryptophan 2,3-dioxygenase (TDO2) to produce immunosuppressive tryptophan metabolites that
undermine patients’ immune systems, leading to poor disease outcomes. Both enzymes are validated
targets for cancer immunotherapy but there is a paucity of potent TDO2 and dual IDO1/TDO2
inhibitors. To identify novel dual IDO1/TDO2 scaffolds, 3D shape similarity and pharmacophore
in silico screening was conducted using TDO2 as a model for both systems. The obtained hits
were tested in cancer cell lines expressing mainly IDO1 (SKOV3—ovarian), predominantly TDO2
(A172—brain), and both IDO1 and TDO2 (BT549—breast). Three virtual screening hits were confirmed
as inhibitors (TD12, TD18 and TD34). Dose response experiments showed that TD34 is the most
potent inhibitor capable of blocking both IDO1 and TDO2 activity, with the IC50 value for BT549 at
3.42 µM. This work identified new scaffolds able to inhibit both IDO1 and TDO2, thus enriching the
collection of dual IDO1/TDO2 inhibitors and providing chemical matter for potential development
into future anticancer drugs.
Keywords: kynurenine; haem-containing dioxygenases; cancer immunotherapy; ligand and
pharmacophore-based screening; molecular modelling; chemical space
1. Introduction
The kynurenine pathway transforms ~95% of the essential amino acid tryptophan into many
bioactive metabolites including nicotinamide adenine dinucleotide (NAD+), crucial for cellular redox
metabolism [1]. Haem-containing enzymes indoleamine 2,3-dioxygenase (IDO1) and tryptophan
2,3-dioxygenase (TDO2) catalyse oxidation of tryptophan into N-formyl-kynurenine, the first and
rate-limiting step in the kynurenine pathway [2]. N-formyl-kynurenine is readily converted into
kynurenine inside mammalian cells by kynurenine formamidase [3]. Whilst both IDO1 and TDO2
catalyse the identical biochemical reaction, their physiological roles and protein structures differ
substantially. TDO2 is a tetramer (167 kDa) expressed predominantly in the liver to maintain
tryptophan homeostasis. In contrast, IDO1 is a monomeric enzyme (37 kDa) essentially absent in most
normal tissues but induced during inflammation and mammalian gestation to suppress the immune
system [1].
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Tryptophan deprivation and the accumulation of tryptophan metabolites such as kynurenine
paralyse cancer-killing immune cells and expand the populations of suppressive immune cells in
tumour microenvironments, contributing to immune escape and malignancy [4,5]. Many cancers
express high levels of TDO2 and IDO1, and high tumoural IDO1 expression is associated with
poor patient outcomes [4,6]. The important role of accelerated tryptophan catabolism in escaping
immune surveillance makes IDO1 and TDO2 prime targets for development of small molecule
drugs to augment cancer immunotherapy. Advanced biochemical assay methodologies [7–9]
and virtual screening approaches [10,11] have played a key part in discovery of a diverse range
of IDO1-specific inhibitors [1,12,13]. Two IDO1 inhibitors, Epacadostat (Incyte Corporation) and
Linrodostat (Bristol-Myers-Squibb), have reached Phase 3 clinical trials [14–16].
Despite promising results in early clinical trials [17], in phase 3 trial ECHO-301, the combination of
Epacadostat and PD-1 inhibitor Pembrolizumab did not provide a large cohort of advanced melanoma
patients with any additional survival benefit compared to Pembrolizumab alone [18]. A potential
explanation for this unfavourable outcome is the expression of both IDO1 and TDO2 in the patients’
tumours [19]. In this situation, an IDO1-specific inhibitor such as Epacadostat cannot completely block
the production of the immunosuppressive tryptophan catabolites because it inhibits TDO2 weakly.
Hence, the combination of IDO1- and TDO2-specific inhibitors or administration of dual IDO1/TDO2
inhibitors are promising strategies being explored to more completely silence the immunosuppressive
kynurenine pathway. However, a relative dearth of potent TDO2-specific [1,15,20] and dual IDO1/TDO2
inhibitors limits advances in this area [21–23].
Structure-based virtual screening is a well-established method to identify hit matter for
development of lead- and drug-candidates when a protein structure is available [24–26]. Virtual hits
need to be tested in a biological assay verifying their affinity for the target of interest. Kynurenine
production can be conveniently monitored in a cell-based assay [27,28] and the crystal structures
of TDO2 and IDO1 are available [29–31]. Herein, we applied the virtual screening technique in
conjunction with the cell based kynurenine assay to identify TDO2-specific and dual IDO1/TDO2
inhibitors with potential for further development into drug candidates for cancer immunotherapy.
2. Results and Discussion
2.1. Validation of Virtual Screening Methods
In order to gauge the prediction power of the virtual screening methodologies available a test set
of active and inactive compounds was compiled. Eighty (80) known TDO2 inhibitors were obtained
from ChEMBL collection [32], and from the literature [33], thirty-four (34) were defined as active
(IC50 ≤ 10 µM) and 46 as inactive ligands (IC50 > 100 µM). The ligands active in the region between
these classifications (10–100 µM) were unfortunately not available in the literature. TDO2 was used as
a model for both systems, the rational being that the same substrates are metabolised into the same
products by both enzymes. An accumulation curve, which shows the number of screened compounds
over the number of actives found in the collection, was plotted for each virtual screening method and
compared to an ideal curve. An RAUC value
(
AUCexperimental
AUCideal
)
was computed to illustrate the comparison
numerically. An RAUC value of 1.0 reflects ideal performance but a value of 0.5 infers no enrichment.
Thus, the accumulation curve of a good-performing method looks similar to the ideal curve whilst a
diagonal line is expected for a method with no prediction power.
2.2. Molecular Docking
Inhibitor 1-(6-chloro-1H-indazol-4-yl)cyclohexan-1-ol (9R9, Figure 1) was re-docked to the TDO2
crystal structure; the predicted pose obtained was very similar to the co-crystallized conformation
(root-mean-square deviation (RMSD) 0.59 Å) demonstrating the prediction power of the method.
However, when docking scores of the test library were plotted against their experimental IC50
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(concentration leading to 50% inhibition of activity), the result showed a poor accumulation curve
approximating a diagonal line with an RAUC value of only 0.64 (Figure 2).
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Figure 2. Accumulation curves for (A) the molecular docking method and (B) pharmacophore
models 1 and 2, compared to the ideal curve (black solid line). Whilst (A) indicates poor enrichment,
pharmacophore model 2 (orange dots) in (B) affords excellent enrichment with RAUC value of 0.98.
2.3. Pharmacophore Modelling
Two pharmacophore based methods were tested, an e-pharmacophore hypothesis derived
from the 9R9-TDO2 complex (pharmacophore model 1) and a manual pharmacophore hypothesis
(pharmacophore model 2) derived from ten active compounds [33–36] of which five effectively inhibit
TDO2 (1a–1e) and five are inactive (2a–2e) (Figure 2). The virtual library was screened against these
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two models. The e-pharmacophore hypothesis yielded poor enrichment (RAUC = 0.59), however the
manual model gave nearly ideal enrichment with RAUC = 0.98 as shown in Figure 2B.
2.4. 3D Shape Similarity
Another ligand-based virtual screening method, 3D shape similarity approach, was tested for its
ability to predict TDO2 inhibitors. The three most active ligands 1a, 1b and 1c (Figure 1) were selected
as query compounds. The virtual library was screened against each using the three methods embedded
in Maestro’s Shape Screening panel. Each structure was treated as (a) a collection of pharmacophore
sites (typed pharmacophore), (b) van der Waals (vdW) volume rewarding overlaps of the same atom
types (typed atoms), and (c) pure vdW volume to treat all atoms the same for defining overlaps
(untyped atoms). The accumulation curves were close to the ideal for the three compounds for the
typed and un-typed atoms mode (Figure 3) but the RAUC values for the typed pharmacophore mode
were considerably lower as shown in Table 1.
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Table 1. RAUC values of the accumulation curves for the query compounds obtained using the three
modes of shape si ilarit scree i .
Query Typed Pharmacophore Typed Atoms Untyped Atoms
1a 0.76 0.95 0.95
1b 0.65 0.90 0.87
1c 0.78 0.96 0.97
The test library results indicate that the 3D shape screening methods, with typed and untyped
atoms using inhibitors 1a and 1c as query compounds gave excellent results. It was therefore decided
to use these methods to screen the InterBioScreen (IBS) natural product library [37] followed by the
pharmacophore model 2. First, the fast 3D shape screening methods were used to quickly reduce
the size of the IBS library followed by the more CPU-intensive pharmacophore model 2, as shown in
Figure 4.
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2.5. Virtual Screening of the IBS Library
The IBS natural compounds library (66,804 molecules) was downloaded, optimised and prepared
for screening resulting in 224,767 molecular entities including different enantiomers, tautomers and
ionization states. The molecular descriptors were generated, the molecular entities < 100 Da and
> 700 Da, Log P > 5 and Log S < −6 were removed. Furthermore, molecules with more than two
Lipinski’s Rule of Five violations were eliminated [38].
The remaining 166,293 entities were screened for their 3D shape similarity to 1a and 1c using the
untyped atoms mode. Entities with shape similarity score ≥ 0.85 to 1a (783 entities/583 compounds)
and those with shape similarity score ≥ 0.80 to 1c (189 entities/164 compounds) were selected for further
screening. The resulting compounds were merged and screened against pharmacophore model 2.
Entries with Phase screen score ≥ 1.0 (35 entries/30 compounds) were selected for biological evaluation.
All the structures are given in Figure S2 in the Supplementary Material section.
2.6. Cell-Based Assays for Testing the Inhibitory Activity of Test Compounds
In order to determine the ability of compounds to inhibit kynurenine production in cancer cells and
their selectivity for IDO1 and TDO2, we first set out to identify cell lines endogenously expressing only
IDO1, only TDO2, and both enzymes simultaneously. It has been reported that the ovarian cancer line
SKOV3 expresses exclusively IDO1 [39] and the glioma line A172 expresses predominantly TDO2 [40],
but a cell line endogenously expressing both enzymes in the absence of interferon stimulation is yet to
be described. To this end, we carried out a meta-analysis of IDO1 and TDO2 transcript abundance
available in 60 common cancer lines in the National Cancer Institute database (Figure 5A). Forty-five
lines (75%) were essentially devoid of dioxygenase transcripts (Figure 5A, grey cluster 1) consistent
with inducible IDO1 expression and the absence of TDO2 in the majority of non-hepatic tissues.
The remaining 15 lines (25%) clustered into ten predominantly TDO2-expressors (clusters 2 and 4),
three IDO1 expressors (clusters 5 and 6) and two dual IDO1/TDO2 expressors (cluster 3).
Molecules 2019, 24, 4346 6 of 19
Molecules 2019, 24, x 6 of 19 
6 
 
 
Figure 5. Identification and characterisation of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 
2,3- dioxygenase (TDO2) expressing cell lines (A) Scatter star plot of normalised TDO2 (y-axis) and 
IDO1 (x-axis) mRNA expression levels (Z-score) of 60 cancer cell lines from the NCI CellMiner CDB 
database [41]. Grey horizontal and vertical line demarcates the lowest Z-score values in the dataset. 
Cell lines are grouped into six clusters based on the unsupervised hierarchical clustering analysis, 
using Ward.D2 clustering of Manhattan distances. Enlarged points indicate centres of each cluster. 
Marginal plots represent histograms. (B) Secreted kynurenine levels and (C) abundance of human 
IDO1 and α-tubulin (loading control) in cancer cell lines studied. Bar height denotes arithmetic mean 
of independent experimental measurements represented as white circles. (D) Inhibitory activity of 
reference IDO1 inhibitor 5L and TDO2 inhibitor 680C91 in A172 glioblastoma, SKOV3 ovarian and 
BT549 breast cancer cell lines. The values inside the plots indicate IC50. 
Consistent with a previous report, SKOV3 expressed the highest levels of IDO1 transcript in this 
meta-analysis [39]. One of the putative dual expressors (cluster 3), breast cancer line BT549, was 
available in our laboratory, hence we proceeded to validate its IDO1 abundance and kynurenine 
production as well as for the positive controls A172 and SKOV3. Furthermore, several negative 
control cell lines predicted to have minimal or no kynurenine expression in Figure 5A were tested 
(Figure 5B,C). Due to the paucity of specific anti-TDO2 commercial antibodies, we decided to assess 
the presence of TDO2 in the cells using a combination of published IDO1-specific and TDO2-specific 
inhibitors Incyte 5L [42] and 680C91 [43], respectively (see Figure 5D for their chemical structures). 
The levels of kynurenine and IDO1 protein produced by the seven lines tested (Figure 5B,C) are 
markedly consistent with the transcript abundance (Figure 5A). The high TDO2 expressor A172 and 
the dual IDO1/TDO2 expressor BT549 produced the highest levels of both IDO1 protein and 
Figure 5. Identification and characterisation of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan
2,3- dioxygenase (TDO2) expressing cell lines (A) Scatter star plot of normalised TDO2 (y-axis) and
IDO1 (x-axis) mRNA expression levels (Z-score) of 60 cancer cell lines from the NCI CellMiner CDB
database [41]. Grey horizontal and vertical line demarcates the lowest Z-score values in the dataset.
Cell lines are grouped into six clusters based on the unsupervised hierarchical clustering analysis,
using Ward.D2 clustering of Manhattan distances. Enlarged points indicate centres of each cluster.
Marginal plots represent histograms. (B) Secreted kynurenine levels and (C) abundance of human
IDO1 and α-tubulin (loading control) in cancer cell lines studied. Bar height denotes arithmetic mean
of independent experimental measurements represented as white circles. (D) Inhibitory activity of
reference IDO1 inhibitor 5L and TDO2 inhibitor 680C91 in A172 glioblastoma, SKOV3 ovarian and
BT549 breast cancer cell lines. The values inside the plots indicate IC50.
Consistent with a previous report, SKOV3 expressed the highest levels of IDO1 transcript in
this meta-analysis [39]. One of the putative dual expressors (cluster 3), breast cancer line BT549,
was available in our laboratory, hence we proceeded to validate its IDO1 abundance and kynurenine
production as well as for the positive controls A172 and SKOV3. Furthermore, several negative control
cell lines predicted to have minimal or no kynurenine expression in Figure 5A were tested (Figure 5B,C).
Due to the paucity of specific anti-TDO2 commercial antibodies, we decided to assess the presence of
TDO2 in the cells using a combination of published IDO1-specific and TDO2-specific inhibitors Incyte
5L [42] and 680C91 [43], respectively (see Figure 5D for their chemical structures).
The levels of ky urenine and IDO1 protein produced by the s ven lines tested (Figure 5B,C) are
mark dly consistent with the transcript abundance (Figure 5A). The high TDO2 expressor A172 and the
dual IDO1/TDO2 expressor BT549 produced the highest levels of both IDO1 protein and kynurenine
whereas IDO1-expressor SKOV3 produced a lower but still substantial amount of kynurenine. The other
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four lines derived from breast and lung cancers secreted less than 4 µM kynurenine and produced
barely detectable amount of IDO1 (Figure 5B,C). Subsequently, the presence of IDO1 and TDO2 in
A172, BT549 and SKOV3 was assessed using small-molecule inhibitors (Figure 5D).
The IDO1-specific inhibitor 5L completely inhibited kynurenine production in SKOV3 at 1 µM
and provided an IC50 value of 10 nM consistent with published results [28,42]. The TDO2-specific
inhibitor 680C91 barely affected SKOV3’s kynurenine production, strongly suggesting TDO2 deficiency
in the SKOV3 line concordant with the meta-analysis in Figure 5A. A172 showed inversed sensitivity
to the two inhibitors tested suggesting IDO1 deficiency. On the other hand, 5L and 680C91 both
inhibited kynurenine production in BT549 albeit between 5- and 10-fold less potently indicative of
dual expression of IDO1 and TDO2.
In conclusion, these experiments support the presence of only IDO1 in SKOV3 and that of TDO2
in A172, and indicate dual expression of IDO1 and TDO2 in BT549. The A172 and SKOV3 lines served
to identify specificity of the inhibitors to IDO1 or TDO2, respectively, and the BT549 line challenged
the ability of the compounds to inhibit both dioxygenases simultaneously.
2.7. Testing the in Silico Hits for Inhibition of IDO1 and TDO2
The thirty virtual hits (designated as TD01 to TD30) identified were subsequently tested for their
ability to inhibit kynurenine production in SKOV3 and BT549 lines. Two hits (TD12 and TD18) were
initially confirmed as kynurenine production inhibitors, indicating a 6% hit rate of the virtual screening.
Both compounds inhibited kynurenine secretion to a similar extent (50% ± 20%) (Figure 6A). A higher
hit ratio would be expected if a recombinant enzyme assay was used because virtual screening does
not take into account cell penetration. In addition, preliminary results indicated that hit TD05 was
active but further investigation did not confirm this finding.
The chemical space surrounding TD05 and the confirmed inhibitors TD12 and TD18 was
investigated by conducting similarity and substructure search of commercially available compounds
in the eMolecules portal [44]. Derivatives of TD12 and TD18 were not commercially available but
five analogues of TD05 were purchased and tested (TD31–35). Their molecular structures are shown
in Figure S3 of the Supplementary Material. Only TD34 inhibited kynurenine production at 20 µM
(Figure 6A) in the absence of cell toxicity. Interestingly, TD34 shares similarity with previously
reported ethylnaphthoquinone derivatives, inhibitors of IDO1 [45]. The molecular structures of the hit
compounds TD12, TD18 and TD34 are shown in Figure 6B. Whilst the inhibitor TD34 is based on a
naphthoquinone core, a class of known IDO1 inhibitors, aromatic diketones TD12 and TD18 are novel.
TD18 is a derivative of TD12 differing only by a larger isopropyl substituent in place of a methyl
group. Similar inhibitory activity of both TD12 and TD18 suggests that the anisole ring of TD12 can
tolerate larger substituents without significant impact on inhibitory activity. In contrast, substitution of
a meta-cresol ring of TD18 by a para-cresol ring (TD28) results in a complete loss of inhibitory activity
(see Figure S2 in the Supplementary Material). This means that the substitution pattern on the phenyl
rings is important for the activity of this series and can be further chemically modified to explore the
structure activity relationship.
The three confirmed IDO1/TDO2 inhibitors (Figure 6B) were titrated for inhibition of kynurenine
secretion in order to determine their potency and selectivity against IDO1 and TDO2 (Figure 6C).
TD34 emerged as the most potent of the three inhibitors. Whilst TD34 inhibits TDO2 in A172 and
IDO1 in SKOV3 relatively weakly (IC50 ~ 40 µM), it shows more than 10-fold higher potency in
the dual IDO1/TDO2 expressing line BT549 (IC50 = 3.45 µM). This appears to be a general trend
amongst the three inhibitors; their potency markedly improves in the BT549 line compared to either
the A172 or SKOV3 lines. This result indicates that all three inhibitors can bind both IDO1 and TDO2
simultaneously. Even though the two enzymes are structurally different, they metabolise the identical
substrate tryptophan, hence the identification of dual IDO1/TDO2 inhibitors is not surprising.
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kynurenine secretion in SKOV3 and BT549 cell lines by the virtual hits TD1 to TD30 and the structural
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cell lines. (B) Chemical structures of the confirmed dioxygenase inhibitors TD12, TD18 and TD34.
(C) Potency of the three confirmed inhibitors in all three cell line models. The values inside the plots
are IC50 values. Data points are arithmetic means ± standard deviations.
To confirm that the compounds are nontoxic, we measured changes in metabolic activity and
growth of the cells treated with a 20 µM inhibitor dose using WST-1 and SRB assays, respectively
(Figure 7). WST-1 tests the bio-reductive potential of the cells as a surrogate of cell fitness whereas
SRB stains total protein content of the cells indicative of cell nu ber. None of the three compounds
affected total protein content or metabolic activity of the cells hen compared to a vehicle treated cell
po ulation (Figure 7B) sug esting that the co t xic at concentrations inhibitory to at
least the BT549 line. None of the thre inhibitors nterfered with IDO1 protein expression as determined
by immunoblotting (Figure 7A). Overall, these obs vations sugg st that the thr e in ibi ors reduce
cellular kynurenine secretion by binding o IDO1/TDO2 rather than interfering with the enzyme
expr ssion or decr asing cellular fitness. Howev r, due to potential redox activity of the inhibitors,
especially TD34, the interference with the reductive activation of IDO1/TDO2 cannot be excluded.
In order to check the redox stability of the ligands, their ionisation potentials (IP) and electron affinities
(EA) were derived using the Density Functional Theory (DFT) method. The IP reflects one-electron
oxidation whereas EA one-electron reduction. The established parameters for known drugs is 6.0
to 9.0 eV for IP and −1.5 to 2.0 eV for EA [46]. TD12 and TD18 have the same IP value 7.5 eV and
again the same EA values of −0.6 eV, comfortably within the 95% confidence limits of known drugs.
It can be stated that these two ligands are redox stable. However, TD34 has an EA value of −2.0 eV,
i.e., half an eV lower than the confidence limits for known drugs and is therefore susceptible for
reduction. Furthermore, TD34 does contain a quinone moiety, which is recognised as one of the
Pan-assay Interference Compounds (PAINS) [47]. Interestingly, TD05, TD31, TD32, TD33 and TD35
also contain quinone but show no or marginal activity. TD35’s IP value is 8.4 eV and within the
specified range.
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Ideally, the hit compounds should be tested in biochemical assays based on the purified enzymes,
verifying their potential and specificity. Nevertheless, the nontoxic nature of the hits indicates that no
vital cellular pathways are perturbed but off-target effects cannot be excluded.
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2.8. Suitability of the Identified Hits for Drug Development—Chemical Space
The mainstream molecular descriptors of molecular weight (MW), number of hydrogen bond
donors (HB donor), number of hydrogen bond acceptors (HA acceptor), lipophilicity (Log P),
polar surface area (PSA) and number of rotatable bonds (RB) were derived for the hit ligands
and are given in Table 2. The ligands are relatively average in size with molecular weight between 284.3
and 375.2 g mol−1. TD12 is in lead-like space since its MW is < 300 g mol−1 whilst TD18 and TD34 are
in drug-like space (for the definition of lead-like, drug-like and Known Drug Space (KDS) regions, readers
are referred to ref. [48] and Table S1 in the Supplementary Material). A similar situation is seen for
Log P, one ligand, TD18, is in the drug-like space with the other two in lead-like space. In general,
the three hits are on the border between lead- and drug-like spaces with no value reaching the larger
KDS. This is most likely due to the pre-filtering based on the molecular descriptors of the library prior
to screening.
Table 2. The molecular descriptors calculated for TD012, TD018 and TD34 as well as their Known
Drug Indexes (KDIs).
MW PSA #Rotor DonorHB AccptHB Log P KDI2a/b
TD12 284.3 73.3 6 1 4.5 2.7 5.70/0.75
TD18 312.4 72.2 7 1 4.5 3.5 5.67/0.71
TD34 375.2 76.0 3 0 6.0 2.6 5.69/0.70
MW: Molecular weight. PSA: Van der Waals surface area of polar nitrogen and oxygen atoms and carbonyl carbon
atoms. #rotor: number of rotatable bonds. donorHB: H bond donor count. accptHB: H bond acceptor count.
Log P: Predicted octanol/water partition coefficient. KDI: Kn wn Drug Index.
For further analysis, the Know Drug Indexes 2a and 2b (KDI2a/2b) [49] were also derived. The KDIs
reflect the overall balance of the six molecular properties calculated based on the statistical distribution
of KDS and derivation of an index for each descriptor. KDI2a is an additive value with a maximum of
6.0 and KDI2b, where the indexes are multiplied, gives 1.0 as its maximum. The average for KDI2a
for known drugs is 4.08 (±1.27) and the hit compounds have considerably higher values. The KDI2b
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version has an average of 0.18 (±0.20) for known drugs and all the ligands have considerable better
scores, indicating excellent bioavailability of the ligands.
2.9. Molecular Modelling for Mechanistic Insights
The pharmacophore hypothesis used was made up of four features, two aromatic rings and two
H-bond acceptors, as well as excluded volumes. TD12 and TD18 aligned well with these features
avoiding the excluded volumes (Figure 8), demonstrating that the benzene rings, the hydroxyl and
carbonyl oxygen atoms on the allyl linker are key pharmacophores. Interestingly, the enol tautomers of
TD12 and TD18 were identified as active in the virtual screening cascade whereas their diketone forms
scored poorly. The molecular modelling is therefore conducted on the enol tautomers. Furthermore,
according to DFT calculations the enol form, of both TD12 and TD18, is only 1.7 kcal mol−1 less stable
than the diketone resulting in a considerable population of the enol.
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Figure 8. Alignment of TD12 (cyan, left-hand side) and TD18 (magenta, right-hand side) to pharmacophore
model 2. The pharmacophore features are shown as orange rings (aromatic ring), pink spheres (H-bond
acceptor), and blue spheres (excluded volumes); feature tolerances are showed as grey spheres around
the pharmacophores.
In order to test this hypothesis and further understand the compounds’ interactions with the
target enzymes, we performed QPLD (QM-Polarized Docking), which provides improved accuracy
but at the expense of long calculation times when compared to the classical molecular mechanics.
This is especially valid in the presence of transition metals by treating partial charges of ligand-receptor
complex with quantum mechanics. This was evident with the RMSD values between the original
conformation of the co-crystallized inhibitors and their docked conformation by extra precision Glide
versus the QPLD approach. These values were 0.59 Å vs. 0.19 Å for 6A4I (TDO2), 0.68 Å vs. 0.42 Å for
5EK3 (IDO1), and vs. 0.53 Å vs. 0.37 Å for 6E43 (IDO1).
TDO2 is composed of four identical subunits each containing four α-helices and a heme cofactor
catalysing oxidation of tryptophan to N-formylkynurenine. The iron at the centre of the heme
is coordinated with six ligands: four with the pyrrole nitrogen atoms from the protoporphyrin;
the fifth with the nitrogen atom of histidine (His328) side chain; and the sixth with an O2 molecule,
substrate tryptophan or an inhibitor [50]. Dissociation of heme groups in heme-containing proteins
is considered as the initial step of inhibition when ligands bind to apo forms of these proteins [51].
So far the 3D structure of only the holo human TDO2 has been identified. On the other hand, available
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crystal structures of apo IDO1 let us evaluate the affinity of the compounds to heme-free, as well as
heme-containing IDO1.
TD12 and TD18 fit to the substrate-specific catalytic site of human TDO2 with high affinity (Table 3).
We observed that the oxygen of 2-hydroxyphenyl of TD12 and the oxygens of 2-isopropyloxyphenyl
and hydroxyallyl of TD18 were within 4 Å of the heme iron (Figure 9). The OH on the allyl linker of
TD12 also donated an H-bond to Ala150 side chain oxygen, which proves the key role of the tautomeric
forms of these compounds in TDO2 inhibition. The compounds were stabilised in the catalytic site by
key interactions with Arg144, Phe72 and His76 via their phenyl rings. The importance of these residues
in the catalytic activity was proved in a mutagenesis study [52]. Some of these interactions were also
detected for the co-crystallized inhibitor. These results support the pharmacophore hypothesis except
the carbonyl oxygen as H-bond acceptor. In this QM-optimized docking the HOMO-LUMO gaps of
the receptor complexes with TD12 and TD18 were found to be −0.098 and −0.085 hartree, respectively,
showing that the inhibitors were stable in the catalytic site.
Table 3. Docking scores (kcal/mol) * for the hit matter.
Ligand 6A4I 5EK3 6E43
TD12 −7.9 −6.4 −7.2
TD18 −7.4 −6.8 −7.4
TD34 −3.9 −6.3 −8.2
* XPGscore from the QM-optimized re-docking.
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chain (Figure 9C). However, the affinity of the TD34-6A41 complex was low. This could be due to 
weak interaction with the heme iron, as the low gap of HOMO-LUMO energies (−0.026 hartree) 
indicated lack of stability for this complex. Thus, TD34 is expected to preferentially bind to the apo 
enzyme. 
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Figure 9. Binding interactions of TD12 (A), TD18 (B) and TD34 (C) with holo human TDO2 active site
residues according to molecular docking. Ligands and heme are shown as colour sticks, protein as
ribbons, and binding interactions as coloured dashed lines, yellow for H-bond, blue for pi–pi, and green
for pi–cation.
In the case of TD34, the 3-bromothiophene ring positioned perpendicular to the heme with the
sulphur atom close to the iron. The ring is predicted to form pi–pi stacking with Phe72 and one of the
oxygen atoms of the 2-methylnaphthalene-1,4-dione ring accepted H-bond from the Arg144 side chain
(Figure 9C). However, the affinity of the TD34-6A41 complex was low. This could be due to weak
interaction with the heme ir n, a the low gap of HOMO-LUMO energies (−0.026 hartree) indicated
lack of stability for this complex. Thus, TD34 is expected to preferentially bind to the apo enzyme.
Unlike TDO2, the catalyti 1 has an a d tional hydrophobic pocket thus can
accom odate larger liga s [ 0]. The compounds, being relatively small, fit well in the catalytic
site, without occupying the additional hydrophobic cavity (HOMO-LUMO gap: −0.103 and −0.099
hartree for TD12 and TD18, respectively) and showing similar orientations as in the TDO2 active
site. The oxygen atoms of 2-hydroxy-4-methylphenyl of TD12 and TD18 were close to the heme iron,
as well as the oxygen of carbonyl of TD12 and hydroxyl of TD18 at the allyl linker, all together forming
a triangle with the iron (Figure 10). In addition, TD12 formed an H-bond via its aromatic hydroxyl with
Ser167 and pi–pi staking with Tyr126, which were reported to take part in the electrostatic interactions
network of co-crystallized inhibitors [51]. Although TD34 showed affinity to the heme-containing
Molecules 2019, 24, 4346 12 of 19
IDO1, an effective interaction with the heme iron or nearby key residues was absent (Figure 10) and
the HOMO-LUMO gap (-0.066 hartree) was quite small.
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Figure 10. Binding interactions of TD12 (A), TD18 (B) and TD34 (C) with holo human IDO1 active
site residues according to molecular docking. Ligands and heme are shown as colour sticks, protein as
ribbons, and pi–pi interactions as blue dashed lines.
Furthermore, TD12 and TD18 bound to the heme-free IDO1 active site with high affinity. Through
the phenolic oxygen, they formed an H-bond with the His346 sidechain (Figure 11), which normally
coordinates with the heme iron in the holo enzyme, indicating that both compounds may also have
affinity to the apo IDO1. TD34 bound strongly to the apo IDO1 by interacting with His346 side chain
via the 2-methylnaphthalene-2,4-dion ring and the bromine moiety from both sides. The bromine
also made electrostatic contacts with the Arg343 side chain, forming an array of interactions among
TD34 and the two residues, which was also the case with the co-crystallized inhibito s of heme-free
IDO1 [32,51]. TD34, as a dual TDO2-IDO1 inhibitor, appears to have stronger affinity to the apo forms
of these enzymes.
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Figure 11. Binding interactions of TD12 (A), TD18 (B) and TD34 (C) with apo human TDO2 active site
residues according to molecular docking. Ligands and heme are showed as colour sticks, protein as
ribbons, and binding interactions as colour dashed lines, yellow for H-bond, violet for halogen bond,
blue for pi–pi, and green for pi–cation.
3. Materials and Methods
3.1. Virtual Screening
Compounds from the test set [32,33] and InterBioScreen Ltd. (IBS, Moscow, Russian
Federation) [37] data bases were structurally optimised using MacroModel (2018-4: Schrödinger, LLC,
New York City, NY, USA, 2018) with the OPLS_2005 force field [53]. The ligands were prepared using
LigPrep module of Maestro (2018-4: Schrödinger, LLC, New York City, NY, 2018) by desalting, creating
possible enantiomers, tautomeric and ionization states at pH 7±2. Their physicochemical descriptors
were calculated using QikProp (version 3.2, New York City, NY, USA, 2018) [54]. The reliability of
it is established for the calculated descriptors [55]. The crystal structures for human TDO2 (PDB ID:
6A4I, resolution 2.65 Å) and IDO1 (5EK3, resolution 2.21 Å [30] and 6E43, resolution 1.71 Å [31])
were downloaded from the Protein Data Bank [56,57] and prepared using Protein Preparation Wizard
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(2018-4: Schrödinger, LLC, New York City, NY, USA, 2018) [58]. Solvent and non-protein residues were
removed, hydrogens were added, missing sidechains were filled with Prime (2018-4: Schrödinger,
LLC, New York City, NY, USA, 2018), ionization and tautomeric states were generated by Epik (2018-4:
Schrödinger, LLC, New York City, NY, USA, 2018), hydrogen orientations were set by Propka. Receptor
grid maps were prepared using Receptor Grid Generation tool of Glide (2018-4: Schrödinger, LLC,
New York City, NY, USA, 2018) by setting the central coordinates of the inhibitor for each pdb structure
as the centre of search space. Each ligand of the test set was docked, keeping the ligands flexible to the
grid, using Glide at extra precision 50 times [59–61]. Pharmacophore modelling was performed with
Phase (2018-4: Schrödinger, LLC, New York City, NY, USA, 2018) using default settings [62,63]. For 3D
shape similarity screening, Maestro’s Shape Screening panel was used. The active compounds from
IBS library (TD12, TD18 and TD34) were docked according to the QM-Polarized Docking (QPLD)
protocol [64] of Maestro (2018-4: Schrödinger, LLC, New York City, NY, USA, 2018). The ligands
were initially docked to the active site using extra precision Glide (five runs), QSite and Jaguar [65]
(2018-4: Schrödinger, LLC, New York City, NY, 2018) were used to calculate single-point energies of
each docking complex using the Density Functional Theory [66]. Partial atomic charges were derived
using electrostatic potential fitting; the ligands were re-docked using Glide again at extra precision (ten
runs) and the best poses were predicted according to Coulomb-van der Waals energies.
For the e-pharmacophore method, the crystal structure of the TDO2-inhibitor 1-(6-chloro-1H-
indazol-4-yl)cyclohexan-1-ol (ligand ID: 9R9) molecular scaffold was used for the pharmacophore
query. 3D shape similarity screening was performed using Maestro’s Shape Screening panel with
default settings.
In order to prepare the accumulation curves and determine the RAUC values, the test set compounds
were ranked according to their respective score from each method (shape similarity score for 3D shape
similarity screen, Phase screen score for pharmacophore screen, and docking score for molecular
docking). Then, the number of active compounds (as defined according to their biological activity
data) among the top 34 scoring compounds was determined. Phase screen score is a scoring function
that evaluates the quantity and quality of ligand feature matching, where quality is defined by site,
vector, and volume scoring components.
3.2. Cell Based Kynurenine Assay and Measurement of Cellular Metabolic Activity
Breast cancer cell lines MCF7, MDA-MB-231, BT549, Hs578T; ovarian cell line SKOV3; glioblastoma
cell line A172 and lung cancer cell line H460 were grown in α-MEMGibco, Grand Island, NY, USA;
ThermoFisher catalogue number 12000022) containing 5% foetal calf serum (Moregate Biotech, Hamilton,
New Zealand), insulin/transferrin/selenium supplement (Roche, Ref-11074547001), added according
to the manufacturer’s instructions, as well as penicillin/streptomycin (100 U/mL and 100 µg/mL,
respectively). The amount of kynurenine produced by the cells was measured as described
previously [67]. Briefly, a well of a 96-well plate received 3.7 × 104 cells which were subsequently
cultured with the addition of 50 µM (BT474 and SKOV3 cells) or 100 µM (A172 cells) of L-tryptophan
(Sigma-Aldrich, St Louis, MO, USA) with or without test compounds at 37 ◦C, 5% CO2 for 18 h. The cell
number seeded was optimised to produce levels of kynurenine <40% of initial tryptophan to avoid
tryptophan starvation and to ensure steady-state IDO1/TDO2 kinetics. Next, the culture supernatants
were transferred into a fresh 96-well plate, incubated with trichloroacetic acid (10% final concentration)
for 20 min at 60 ◦C to release kynurenine from the cells and precipitate proteins. After spinning the plates
for 20 min at 2500 g, the supernatants were mixed at a 1:1 ratio with 4-(dimethylamino)benzaldehyde
(20 mg/mL in acetic acid; Sigma) and the absorbance was read at 480 nm on an EnSpire 2300 Multimode
Plate Reader (Perkin-Elmer, Singapore, Singapore). The remaining cells in the 96-well plate received a
well-established indicator of cellular metabolic activity WST-1 (Roche Diagnostics Cat No 05015944,
Basel, Switzerland; 10% diluted in culture media). After 1 h of incubation at 37 ◦C, the absorbance was
measured at 440 nm [68]. WST-1 is reduced on the outer membrane of viable cells to a soluble formazan
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by reducing equivalents such as NAD(P)H. The absorbance measured at 440 nm indicates the number
of metabolically active cells in the culture and represents a surrogate marker of cell viability.
As described previously [69], the sulforhodamine B colorimetric assay (SRB), which is based
on the measurement of cellular protein content, was used to measure cell density [70]. After drug
treatment for 3 d, cells were fixed with 10% (w/v) trichloroacetic acid and stained for 30 min, and the
excess dye was removed by washing repeatedly with 1% (v/v) acetic acid. The protein-bound dye was
dissolved in Tris base solution (10 mM) for optical density determination at 510 nm using a microplate
reader. Optimal cell densities were previously determined to select initial cell densities that ensured
that cells were in logarithmic phase for the experiments.
All experiments were repeated independently at least twice in technical quadruplicates.
Calculations and graph plotting were performed in Prism (v8, 2018; GraphPad software, San Diego,
CA, USA) and R computing environment (v3.5.3, 2019, 64-bit, Vienna, Austria). IC50 of the compounds
in cellular enzymatic activity compared to untreated control cells was determined by fitting data to an
equation f(x) = A + B/(1 + (IC50/X)ˆHILL) in Prism; where A is the minimum and B is the maximum of
the curve, HILL is the slope of the curve and X is the compound concentration.
3.3. Western Blotting
This procedure was carried out as described previously [69,71,72]. Breast cancer cell lines
were grown to log-phase, washed twice with ice-cold PBS, and lysed in a SDS lysis buffer (60 mM
Tris-HCl (pH 6.8 at 25 ◦C), 2% (w/v) SDS, 10% glycerol). Protein concentration was quantified using
the bicinchoninic acid reagent (Sigma). Proteins (25 µg) were separated by SDS-polyacrylamide
gel electrophoresis (PAGE), and transferred to PVDF membranes (Millipore Merck, Auckland,
New Zealand). Membranes were immunoblotted with antibodies against human IDO1 and tubulin
(Sigma). Bound antibody was visualized using Pierce™ ECL Western Blotting Substrate (ThermoFisher
Scientific) and the chemiluminescence measured using image analyser LAS-3000 (Fujifilm, Tokyo,
Japan).
3.4. Density Functional Theory
The geometry optimisation and energy calculations were performed with Gaussian 16 [73]
software using restricted DFT. The non-local B3LYP [74,75] functional hybrid method was employed
and the standard 6-31+G(d, p) [76,77] diffused basis set was used for the geometry optimisation and
frequency analysis vacuum. The zero-point vibrational energies (ZPE) were scaled according to Wong
(0.9804) [78]. In all cases, the normal modes revealed no imaginary frequencies indicating that they
represent minima on the potential energy surface. The subsequent energy calculations were performed
with the larger 6-311+G(2df, p) basis set in vacuum. The ionisation potentials and electron affinities
were calculated as described by Forseman and Frisch [79].
4. Conclusions
Ligand- and pharmacophore-based virtual screening was conducted against the heme containing
enzymes IDO1 and TDO2. They catalyse the same rate-limiting step in the kynurenine pathway,
an important biochemical mechanism for immunological response. ~6.7×104 natural products were
screened resulting in thirty virtual hits, which were tested in three cancer cell lines. These were
glioma A172 only with TDO2 expression, ovarian SKOV3, which only expresses IDO1 and finally
the breast cancer cell line BT549, which expresses both enzyme. Three active dual inhibitors were
identified: TD12, TD18 and TD34, with good kynurenine suppression with an IC50 of 3.42 µM for
BT549 (TD34). Given the expression of both IDO1 and TDO2 in tumours, inhibiting only IDO1 is
unlikely to generate desirable clinical outcomes. Hence, it can be argued that TDO2 needs to be
inhibited as well as making dual inhibitors desirable for further development of drug candidates for
inhibition of the immunosuppressive tryptophan catabolism mediated by IDO1/TDO2. TD12 and
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TD18 are close structural derivatives whereas TD34 is a 1,4-quinone derivative. All have favourable
physicochemical properties and are chemically tractable for further development.
Supplementary Materials: The following are available online, Figure S1. Structure of the active and inactive
compounds of the test set, Figure S2. The thirty structures of the virtual hits (TD01 to TD30), which were tested for
activity, Table S1. Definition of lead-like, drug-like and Known drug space (KDS) in terms of molecular descriptors,
Table S2. The catalogue numbers of the commercial compounds tested and their source, Table S3. The single point
and corrected zero point vibrational energies (ZPE) of the optimized ligands in hartrees (a.u.).
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